Study identifier:D9181C00002
ClinicalTrials.gov identifier:NCT06932263
EudraCT identifier:N/A
CTIS identifier:2024-519116-14-00
A Phase IIb, Multicentre, Double-blind, Placebo-controlled Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adult Participants With Uncontrolled Asthma on Medium-to High Dose Inhaled Corticosteroids
asthma
Phase 2
No
Tozorakimab, Placebo
All
540
Interventional
18 Years - 75 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Sept 2025 by AstraZeneca
AstraZeneca
-
This is a dose-range finding, double-blind, placebo-controlled, phase IIb study designed to assess efficacy and safety of tozorakimab administered subcutaneously in adult participants with uncontrolled asthma receiving medium-to-high dose inhaled corticosteroids.
Location
Status
Location
Maspeth, NY, United States, 11378
Status
Recruiting
Location
Warren, MI, United States, 48088
Status
Withdrawn
Location
Farmington Hills, MI, United States, 48336
Status
Recruiting
Location
Indianapolis, IN, United States, 46268
Status
Recruiting
Location
Miami, FL, United States, 33155
Status
Recruiting
Location
Bellevue, NE, United States, 68123
Status
Withdrawn
Location
Medford, OR, United States, 97504
Status
Recruiting
Location
Asheville, NC, United States, 28803
Status
Withdrawn
Arms | Assigned Interventions |
---|---|
Experimental: Tozorakimab Dose 1 Dosing subcutaneously tozorakimab Dose 1 | Drug: Tozorakimab The drug will be administered subcutaneously. |
Experimental: Tozorakimab Dose 2 Dosing subcutaneously tozorakimab Dose 2 and placebo | Drug: Tozorakimab The drug will be administered subcutaneously. |
Placebo Comparator: Placebo Dosing subcutaneously with equivalent volume to tozorakimab | Drug: Placebo Placebo will be administered subcutaneously. |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.